• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Investor Forum Agenda Announced for June 11th-12th

    6/10/25 2:38:09 PM ET
    $ATNM
    $BPTH
    $COCH
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNM alert in real time by email

    NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research.

    Individual investors, institutional investors, advisors, and analysts are invited to attend.

    REGISTER HERE

    It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.

    "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering companies a direct line to investors," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "This Virtual Investor Conference, co-hosted by Zacks Small Cap Research, offers an essential platform for companies to share their vision, showcase scientific progress, and connect with a wider investment community actively seeking the next wave of healthcare and biotech leaders."

    June 11th

    Eastern

    Time (ET)
    PresentationTicker(s)
    1:00 PM ETNika Pharmaceuticals(OTCQB:NIKA)
    1:30 PM ETTivic Health Systems Inc.(NASDAQ:TIVC)
    2:00 PM ETAdia Nutrition, Inc.(OTCQB:ADIA)
    2:30 PM ET Sandoz Group AG(OTCQX:SDZNY, SIX: SDZ))



    June 12
    th

    Eastern

    Time (ET)
    PresentationTicker(s)
    9:00 AM ETCSL Ltd.(OTCQX:CSLLY, ASX: CSL))
    9:30 AM ETSharps Technology, Inc.(NASDAQ:STSS)
    10:00 AM ETHeidelberg Pharma AG(XETRA: HPHA)
    10:30 AM ETSBC Medical Group Holdings Incorporated(NASDAQ:SBC)
    11:00 AM ETActinium Pharmaceuticals, Inc.(NYSE:ATNM)
    11:30 AM ETImunon, Inc.(NASDAQ:IMNN)
    12:00 PM ETBio-Path Holdings, Inc.(OTCQB:BPTH)
    12:30 PM ETPerimeter Medical Imaging AI, Inc.(OTCQX:PYNKF, TSXV:PINK)
    1:00 PM ETMetaVia Inc.(NASDAQ:MTVA)
    2:00 PM ETConavi Medical Corp.(OTCQB:CNVIF, TSXV:CNVI)
    2:30 PM ETVycor Medical, Inc.(OTCQB:VYCO)
    3:00 PM ETEnvoy Medical, Inc.(NASDAQ:COCH)
    3:30 PM ETStarpharma Holdings Ltd.(OTCQX:SPHRY, ASX: SPL))



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $ATNM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNM
    $BPTH
    $COCH
    $IMNN

    CompanyDatePrice TargetRatingAnalyst
    MetaVia Inc.
    $MTVA
    12/30/2024$12.00Buy
    H.C. Wainwright
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    8/7/2024$16.00 → $2.00Buy → Neutral
    B. Riley Securities
    Envoy Medical Inc.
    $COCH
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    5/14/2024$25.00Overweight
    Stephens
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    9/6/2023$11.60Buy
    HSBC Securities
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    2/21/2023Outperform → Mkt Perform
    William Blair
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    9/8/2022$20.00Overweight
    Cantor Fitzgerald
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    8/25/2022$16.00Buy
    B. Riley Securities
    More analyst ratings

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on MetaVia with a new price target

    H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    12/30/24 7:25:48 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actinum Pharma downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously

    8/7/24 12:40:34 PM ET
    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

    Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

    6/24/24 7:29:10 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    SEC Filings

    View All

    SEC Form 424B3 filed by SBC Medical Group Holdings Incorporated

    424B3 - SBC Medical Group Holdings Inc (0001930313) (Filer)

    8/15/25 6:30:32 AM ET
    $SBC
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MetaVia Inc.

    SCHEDULE 13G/A - MetaVia Inc. (0001638287) (Subject)

    8/14/25 9:15:59 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Bio-Path Holdings Inc.

    10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    8/14/25 5:03:40 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Danner Paul K bought $100 worth of Series B Preferred Stock (5 units at $20.00) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    7/18/25 2:48:21 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Patel Mona Chetan bought $3,675 worth of shares (2,500 units at $1.47), increasing direct ownership by 14% to 20,000 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    6/13/25 4:10:30 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    6/10/25 4:11:23 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense's premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation in support of warfighter health and readiness. Direct Access to DoD Decision-Makers and Researchers MHSRS provides direct access to organizations seeking military partnerships and connects companies with key funding organizations.

    8/15/25 8:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Reports Second Quarter 2025 Financial Results

    Company advances its TLR5 agonist program and prepares to report VNS clinical data Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. "We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems," stated Tivic CEO Jennifer Ernst. "To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit

    8/14/25 4:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SBC Medical Group Holdings Announces Second Quarter 2025 Financial Results

    SBC Medical Group Holdings Incorporated (NASDAQ:SBC, "SBC Medical" or the "Company")), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for the second quarter of fiscal year 2025 (three months ended June 30, 2025) and for the first half of fiscal year 2025 (six months ended June 30, 2025). Second Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $15 million, representing a 47% year-over-year decrease. Net Income attributable to SBC Medical Group was $2.5 million, representing an 87% year-over-year decrease.

    8/13/25 6:55:00 AM ET
    $SBC
    Medical/Nursing Services
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H gifted 14,200 shares, decreasing direct ownership by 32% to 30,079 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    8/13/25 4:36:41 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Zikria Dean

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    8/8/25 6:46:44 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Chief Financial Officer Wolf Lisa G

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    8/8/25 6:46:28 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Leadership Updates

    Live Leadership Updates

    View All

    SBC Medical Appoints Dr. Steven R. Cohen as Medical Strategy Advisor to Accelerate Global Expansion

    SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("SBC Medical"), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the appointment of Dr. Steven R. Cohen, a globally recognized leader in plastic and craniofacial surgery, as Medical Strategy Advisor. His appointment marks a significant step in the company's strategy to expand its global footprint and enhance its medical excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714547888/en/Dr. Cohen Dr. Cohen is the Founder of Faces+, an advanced aesthetic and reconstructive surgery center

    7/14/25 9:00:00 AM ET
    $SBC
    Medical/Nursing Services
    Health Care

    SBC Medical Appoints New Chief Marketing Officer to Enhance Marketing Infrastructure and Strengthen Brand Power

    IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("SBC Medical"), a global franchise and provider of services for aesthetic clinics, is pleased to announce the appointment of Shinya Inoue as Chief Marketing Officer (CMO), effective July 1, 2025. As CMO of SBC Medical, Mr. Inoue will lead efforts to enhance the brand value of the group's portfolio, including Shonan Beauty Clinic, one of Japan's largest aesthetic medical brands. He will also spearhead the evolution and optimization of the company's marketing infrastructure with a strong focus on digital innovation. Through strategic initiatives that address the increasing diversity of

    7/1/25 8:00:00 AM ET
    $SBC
    Medical/Nursing Services
    Health Care

    Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

    Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

    2/24/25 8:15:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    11/14/24 5:37:34 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Imunon Inc.

    SC 13G/A - Imunon, Inc. (0000749647) (Subject)

    11/14/24 12:17:50 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Envoy Medical Inc.

    SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

    11/14/24 8:49:34 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Financials

    Live finance-specific insights

    View All

    Tivic Reports Second Quarter 2025 Financial Results

    Company advances its TLR5 agonist program and prepares to report VNS clinical data Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. "We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems," stated Tivic CEO Jennifer Ernst. "To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit

    8/14/25 4:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SBC Medical Group Holdings Announces Second Quarter 2025 Financial Results

    SBC Medical Group Holdings Incorporated (NASDAQ:SBC, "SBC Medical" or the "Company")), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for the second quarter of fiscal year 2025 (three months ended June 30, 2025) and for the first half of fiscal year 2025 (six months ended June 30, 2025). Second Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $15 million, representing a 47% year-over-year decrease. Net Income attributable to SBC Medical Group was $2.5 million, representing an 87% year-over-year decrease.

    8/13/25 6:55:00 AM ET
    $SBC
    Medical/Nursing Services
    Health Care

    Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 793820 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/52776 About Tivic Health Systems, Inc. Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients' immune system. The company's

    8/7/25 8:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care